The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Does neoadjuvant FOLFOX chemotherapy improve the oncological prognosis of high-risk stage II and III colon cancers ? Three years’ follow-up results of the Prodige 22 phase II randomized multicenter trial.
 
Medhi Karoui
No Relationships to Disclose
 
Claire Gallois
Consulting or Advisory Role - Sanofi; SERVIER
Travel, Accommodations, Expenses - Amgen
 
Guillaume Piessen
Consulting or Advisory Role - Amgen Astellas BioPharma; Bristol-Myers Squibb; Medtronic; MSD Oncology; Nestle health science
 
Jean-Louis Legoux
Consulting or Advisory Role - Novartis; SERVIER
Speakers' Bureau - Keocyt
Research Funding - Novartis/Pfizer; Sanofi/Regeneron (Inst)
Travel, Accommodations, Expenses - Ipsen; Merck Serono; Novartis; SERVIER
 
Emilie Barbier
No Relationships to Disclose
 
Cecile De Chaisemartin
No Relationships to Disclose
 
Cedric Lecaille
No Relationships to Disclose
 
Olivier Bouché
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Merck Serono; MSD Oncology; Roche
Speakers' Bureau - Amgen; Pierre Fabre; Sanofi; Servier
Travel, Accommodations, Expenses - Merck Serono; Roche; Servier
 
Hanifa Ammarguellat
No Relationships to Disclose
 
Francesco Brunetti
No Relationships to Disclose
 
Michel Prudhomme
No Relationships to Disclose
 
Jean-Marc Regimbeau
No Relationships to Disclose
 
Olivier Glehen
Honoraria - Gamida Cell
Consulting or Advisory Role - Gamida Cell
Speakers' Bureau - Roche
 
Astrid Lièvre
Honoraria - Advanced Accelerator Applications; Amgen; Bayer; Bristol-Myers Squibb; Celgene; HalioDx; Ipsen; Lilly; Merck; Novartis; Pierre Fabre; Roche; Sandoz; SERVIER
Consulting or Advisory Role - Advanced Accelerator Applications; Amgen; Bayer; Incyte; Ipsen; Merck; Novartis; Pierre Fabre; Sandoz; SERVIER
Research Funding - Incyte; IntegraGen; Novartis
Travel, Accommodations, Expenses - Advanced Accelerator Applications; Bayer; Ipsen; Merck; Novartis; Pfizer; Roche; SERVIER
 
Guillaume Portier
No Relationships to Disclose
 
Johannes Hartwig
No Relationships to Disclose
 
Gael Goujon
No Relationships to Disclose
 
Benoît Romain
No Relationships to Disclose
 
Come Lepage
Honoraria - Amgen; Amgen; Bayer
Consulting or Advisory Role - Advanced Accelerator Applications; Novartis
Travel, Accommodations, Expenses - Bayer; Ipsen; Ipsen; Merck Serono; Novartis; Novartis; Sanofi/Aventis
 
Julien Taieb
Consulting or Advisory Role - Amgen; Celgene; Lilly; Merck KGaA; MSD; Pierre Fabre; Roche; SERVIER; Sirtex Medical
Speakers' Bureau - Amgen; Lilly; Merck; MSD; Pierre Fabre; Roche/Genentech; Sanofi; SERVIER